Potentially inappropriate prescribing

可能不适当的处方
  • 文章类型: Journal Article
    老年人通常会遇到潜在的不适当处方(PIP);然而,关于老年高血压患者PIP发生的信息有限.这项研究旨在确定和比较PIP的患病率及其与医院和社区卫生中心(CHC)老年高血压门诊患者合并症的关系。
    这项为期3年(2015-2017年)的重复横断面研究使用了来自深圳的电子病历,中国,涉及62家医院和678家基层医疗机构。PIP使用2019年啤酒标准定义。包括患有高血压的老年人(≥65岁)和至少一个门诊处方。改良泊松回归分析用于评估慢性合并症之间的关联,医疗保健设置,和PIP。
    2015年、2016年和2017年老年高血压门诊患者中PIP的患病率为46.32%,46.98%,医院占46.58%,样本量分别为38411、46235和50495,和29.14%,26.66%,和29.84%的CHC,样本量分别为26,876、29,434和34,775。医院和CHC中最受欢迎的四大PIP是质子泵抑制剂(PPI),利尿剂,苯二氮卓类药物,和非环氧化酶选择性非甾体抗炎药(NSAIDs),分别。PIP与医院中的慢性胃肠道疾病(调整后的患病率=1.54,95%置信区间[CI]=1.50-1.59)和精神和行为障碍(调整后的患病率=1.49,95%CI=1.46-1.53)以及精神和行为障碍(调整后的患病率=1.99;95%CI=1.95-2.03)和肌肉骨骼系统和结缔组织疾病(调整后的患病率=1.33-95%)PIP在医院中的患病率明显高于CHC(调整后的患病率=1.65;95%CI=1.63-1.66)。
    深圳老年高血压门诊患者中,PIP在医院比在CHC中更普遍。与PIP最密切相关的合并症是慢性胃肠道疾病和医院中的精神和行为障碍以及CHCs中的精神和行为障碍。需要考虑临床药学整合,以减少这一弱势群体的不适当处方。
    UNASSIGNED: Potentially inappropriate prescribing (PIP) is commonly encountered in older adults; yet, there is limited information on the occurrence of PIP among older adults with hypertension. This study aims to determine and compare the prevalence of PIP and its association with comorbidities in older adult outpatients with hypertension across hospitals and community health centers (CHCs).
    UNASSIGNED: This 3-year (2015-2017) repeated cross-sectional study used electronic medical records from Shenzhen, China, involving 62 hospitals and 678 primary medical institutions. PIP was defined using the 2019 Beers Criteria. Older adults (≥65 years) with hypertension and at least one outpatient prescription were included. Modified Poisson regression analysis was used to assess the association between chronic comorbidities, healthcare settings, and PIP.
    UNASSIGNED: The prevalence of PIP in old adult outpatients with hypertension in 2015, 2016, and 2017 was 46.32%, 46.98%, and 46.58% in hospitals, with a sample size of 38,411, 46,235, and 50,495, respectively, and 29.14%, 26.66%, and 29.84% in CHCs, with a sample size of 26,876, 29,434, and 34,775 respectively. The top four most popular PIP in hospitals and CHCs was proton-pump inhibitors (PPIs), diuretics, benzodiazepines, and non-cyclooxygenase-selective non-steroidal anti-inflammatory drugs (NSAIDs), respectively. PIP was most associated with chronic gastrointestinal disease (adjusted prevalence ratio = 1.54, 95% confidence interval [CI] = 1.50-1.59) and mental and behavioral disorders (adjusted prevalence ratio = 1.49, 95% CI = 1.46-1.53) in hospitals and with mental and behavioral disorders (adjusted prevalence ratio = 1.99; 95% CI = 1.95-2.03) and musculoskeletal system and connective tissue disorders (adjusted prevalence ratio = 1.33; 95% CI = 1.31-1.36) in CHCs. The prevalence of PIP was significantly higher in hospital settings than in CHCs (adjusted prevalence ratio = 1.65; 95% CI = 1.63-1.66).
    UNASSIGNED: Among older adult outpatients with hypertension in Shenzhen, PIP was more prevalent in hospitals than in CHCs. The comorbidities most strongly associated with PIP were chronic gastrointestinal disease and mental and behavioral disorders in hospitals and mental and behavioral disorders in CHCs. Clinical pharmacy integration needs to be considered to reduce inappropriate prescribing in this vulnerable population.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:有效使用抗菌药物可提高护理质量并对抗抗生素耐药性。然而,非指南因素影响潜在的不适当处方。这项研究探讨了主要医生认为的抗菌药物处方中的心理社会组织因素,次要,和三级护理。方法:遵守PRISMA指南,我们在2000年1月1日至2023年3月8日期间使用PubMed和Scopus数据库进行了系统评价,并在2024年1月30日之前进行了更新检索.纳入标准集中于欧洲的研究,从医院医生的角度探索抗生素处方的心理社会组织因素,住院,或初级保健设置。排除标准针对办公室外处方或低质量研究。为了评价后者,我们使用了几个质量和偏倚风险检查表.根据研究特征提取数据,研究设计,和抗生素处方的方法和确定的决定因素。使用叙事综合方法分析数据。结果:在8370篇文章中,58符合纳入标准,来自23个国家的35篇文章。出现了三个主要主题:个人,心理,和组织因素,包括七个决定因素,包括工作经验,知识,指导方针坚持,不确定性管理,感知压力,时间限制,和诊断资源可用性。不确定性管理是关键,有工作经验和知识减轻它。在更新的搜索中没有出现其他因素。结论:增强的不确定性管理降低了患者和/或父母处方抗生素的压力,有助于减少潜在的不适当处方(PIP)。因此,必须教育医生有效管理不确定性。改善抗生素处方的干预措施应根据不同处方医生的具体需求和偏好进行调整。
    Purpose: Effective antimicrobial use enhances care quality and combats antibiotic resistance. Yet, non-guideline factors influence potentially inappropriate prescribing. This study explores psycho-socio-organisational factors in antimicrobial prescribing as perceived by physicians across primary, secondary, and tertiary care. Methods: Adhering to PRISMA guidelines, a systematic review was conducted using PubMed and Scopus databases from 1 January 2000, to 8 March 2023, with an update search until 30 January 2024. Inclusion criteria focused on studies in Europe exploring psycho-socio-organisational factors for antibiotic prescribing from physicians\' perspectives in hospital, inpatient, or primary care settings. Exclusion criteria targeted out-of-office prescriptions or low-quality studies. To evaluate the latter, several quality and risk-of-bias checklists were used. Data were extracted on study characteristics, study design, and methods and identified determinants of antibiotic prescribing. Data was analysed using a narrative synthesis method. Results: Among 8370 articles, 58 met inclusion criteria, yielding 35 articles from 23 countries. Three main themes emerged: personal, psychological, and organisational factors, encompassing seven determinants including work experience, knowledge, guideline adherence, uncertainty management, perceived pressure, time constraints, and diagnostic resource availability. Uncertainty management was key, with work experience and knowledge mitigating it. No additional factors emerged in the updated search. Conclusion: Enhanced uncertainty management decreases perceived patient and/or parental pressure to prescribe antibiotics, contributing to reducing potentially inappropriate prescribing (PIP). Therefore, it is imperative to educate physicians on effectively managing uncertainty. Interventions to improve antibiotic prescribing should be tailored to the specific needs and preferences of the different prescribing physicians.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:潜在不适当的处方(PIP)是指具有较高不良结局风险的药物处方,如药物相互作用,falls,和认知障碍。PIP在老年人中尤其令人关注,并与发病率增加有关,死亡率,和医疗费用。社会经济匮乏已被确定为PIP的潜在风险因素。然而,这种关系的程度尚不清楚。这篇综述旨在综合当前有关老年人PIP与社会经济地位(SES)之间关联的文献。
    方法:使用Medline数据库进行文献检索,Embase和CINAHL。开发了一种搜索策略来捕获研究三个关键概念的论文:PIP,社会经济匮乏和老年人/老年人口。在2000年1月1日至2022年12月31日之间发表的同行评审定量研究有资格纳入。
    结果:来自3,966个命中的20篇文章符合纳入标准。纳入研究的样本量从668到1650万人不等,其中大部分来自欧洲(n=8)和北美(n=8)。大多数将老年患者定义为65岁或以上(n=12),并使用收入(n=7)或补贴资格(n=5)来评估SES。总之,12项研究报告了社会经济剥夺与经历PIP的可能性增加之间的统计学显著关联。其中一些报告称,在调整了服用药物的数量后,有一些关联,或者多重用药的存在。关联的根本原因尚不清楚,尽管一项研究发现,剥夺和较高的PIP患病率之间的关联不能用获得医疗机构或从业人员的机会较差来解释.
    结论:研究结果表明,老年人的SES与他们暴露于PIP的可能性之间存在某种关联。SES似乎是独立和协同作用以影响老年人经历PIP的可能性的几个因素之一。这篇评论强调,在进行药物审查时,优先考虑生活在社会经济贫困环境中的老年人可能是一种有效的策略。
    BACKGROUND: Potentially inappropriate prescribing (PIP) refers to the prescription of medications that carry a higher risk of adverse outcomes, such as drug interactions, falls, and cognitive impairment. PIP is of particular concern in older adults, and is associated with increased morbidity, mortality, and healthcare costs. Socioeconomic deprivation has been identified as a potential risk factor for PIP. However, the extent of this relationship remains unclear. This review aimed to synthesize the current literature on the association between PIP and socioeconomic status (SES) in older adults.
    METHODS: A literature search was conducted using the databases Medline, Embase and CINAHL. A search strategy was developed to capture papers examining three key concepts: PIP, socioeconomic deprivation and older/elderly populations. Peer-reviewed quantitative research published between 1/1/2000 and 31/12/2022 was eligible for inclusion.
    RESULTS: Twenty articles from 3,966 hits met the inclusion criteria. The sample size of included studies ranged from 668 to 16.5million individuals, with the majority from Europe (n = 8) and North America (n = 8). Most defined older patients as being 65 or over (n = 12) and used income (n = 7) or subsidy eligibility (n = 5) to assess SES. In all, twelve studies reported a statistically significant association between socioeconomic deprivation and an increased likelihood of experiencing PIP. Several of these reported some association after adjusting for number of drugs taken, or the presence of polypharmacy. The underlying reasons for the association are unclear, although one study found that the association between deprivation and higher PIP prevalence could not be explained by poorer access to healthcare facilities or practitioners.
    CONCLUSIONS: The findings suggest some association between an older person\'s SES and their likelihood of being exposed to PIP. SES appears to be one of several factors that act independently and in concert to influence an older person\'s likelihood of experiencing PIP. This review highlights that prioritising older people living in socioeconomically-deprived circumstances may be an efficient strategy when carrying out medication reviews.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:2019年,对老年精神病住院患者的精神药物潜在不适当处方(PIP)进行了区域调查,强调了其在该人群中的不适当使用。这项研究的目的是评估临床相关性-定义为提供适当和必要的治疗,从其他替代方案中选择为最有可能产生给定患者的预期结果-根据当前既定标准,这些处方被认为是不合适的。
    方法:年龄在75岁或64至75岁以上且患有至少一种PIP的精神药物或具有高抗胆碱能负担的药物的患者,由根据STOPP/STARTv2标准和住院48小时处方上的Laroche清单建立的审核网格确定,包括在内。处方不适当性质的权衡(对治疗的抵抗力,危机时期,合并症...)是由药剂师-精神病医生对当前情节的整个计算机化记录建立的。PIP和总体处方的临床相关性被评为0(无关),1(部分相关)或2(相关)。
    结果:纳入34例患者。注意到125种精神药物的PIP:50.4%涉及苯二氮卓类药物和非苯二氮卓类药物抗焦虑药(BZD/Z),25.6%抗精神病药(NL),12%的抗抑郁药(ATD)和12%的药物具有高抗胆碱能负担。一方面,BZD/Z的PIP的49.2%,50%的NL的PIP和20%的ATD的PIP被认为是不相关的。另一方面,BZD/Z的PIP的49.2%,NL的31.3%的PIP和ATD的13.3%的PIP被认为是部分相关的。此外,1.6%的BZD/Z的PIP,18.8%的NLPIP和66.7%的ATDPIP被认为是相关的。对于具有高抗胆碱能负担的药物的PIP,80%被认为无关紧要,13.3%部分相关,6.7%相关。总之,在研究的34种药物处方中,三人(8.8%)被认为无关紧要,11(32.4%)部分相关,20(58.8%)临床相关。
    结论:这项研究强调了根据目前的PPI标准,超过一半的处方被认为不适合老年人的临床相关性。它强调了一种新的PPI检测工具对患有精神疾病的老年患者的兴趣。
    OBJECTIVE: In 2019, a regional survey of potentially inappropriate prescriptions (PIP) of psychotropic drugs in elderly psychiatric inpatients was carried out highlighting their inappropriate use in this population. The aim of this study was to assess the clinical relevance - defined as the provision of an appropriate and necessary treatment, chosen from other alternatives as being the most likely to produce the expected results for a given patient - of these prescriptions considered inappropriate according to current established criteria.
    METHODS: Patients aged over 75, or 64 to 75 and polypathological with at least one PIP of psychotropic drugs or drugs with a high anticholinergic burden, identified by an audit grid established on the basis of STOPP/STARTv2 criteria and the Laroche list on the prescription at 48h of hospitalization, were included. The weighing of the inappropriateness nature of the prescription (resistance to treatment, period of crisis, comorbidities…) was established by a pharmacist-psychiatrist pair on the entire computerized record of the current episode. The clinical relevance of the PIP and the overall prescription was rated as 0 (irrelevant), 1 (partially relevant) or 2 (relevant).
    RESULTS: Thirty-four patients were included. One hundred and twenty-five PIP of psychotropic drugs were noted: 50.4% concerned benzodiazepines and non-benzodiazepines anxiolytics (BZD/Z), 25.6% neuroleptics (NL), 12% antidepressants (ATD) and 12% drugs with a high anticholinergic burden. On one hand, 49.2% of PIP of BZD/Z, 50% of PIP of NL and 20% of PIP of ATD were considered irrelevant. On the other hand, 49.2% of PIP of BZD/Z, 31.3% of PIP of NL and 13.3% of PIP of ATD were considered partially relevant. Furthermore, 1.6% of PIP of BZD/Z, 18.8% of PIP of NL and 66.7% of PIP of ATD were considered relevant. For PIPs of drugs with a high anticholinergic burden, 80% were deemed irrelevant, 13.3% partially relevant and 6.7% relevant. In all, of the 34 drug prescriptions studied, three (8.8%) were considered irrelevant, 11 (32.4%) partially relevant and 20 (58.8%) clinically relevant.
    CONCLUSIONS: This study highlighted the clinical relevance of more than half the prescriptions considered inappropriate according to current PPI criteria in the elderly. It underlines the interest of a new PPI detection tool for elderly patients with psychiatric disorders.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:这项研究旨在比较血液透析患者和不需要肾脏替代疗法的慢性肾脏病患者中潜在不当处方药物的患病率,以及确定与潜在不适当处方相关的风险因素。
    方法:该研究是在肾内科进行的横断面研究,Nis临床中心,塞尔维亚。将患者分为两组:(1)接受血液透析治疗的患者和(2)未接受肾脏替代治疗的不同程度慢性肾脏病患者。使用2015年AGSBeers标准确定是否存在潜在的不适当处方。
    结果:该研究共纳入了218名65岁及以上的患者。血液透析患者之间使用潜在不适当处方药的患者人数没有显着差异(卡方=0.000,p=1.000)(83例中的27例,即,32.5%)和未进行肾脏替代治疗的不同程度慢性肾脏病患者(135例中的44例,即32.6%)。与血液透析患者潜在不适当处方相关的因素是药物数量(风险比[HR]=1.919,95%置信区间[CI]:1.325-2.780)和合并症数量(HR=1.743,95%CI:1.109-2.740)。药物数量(HR=1.438,95%CI:1.191-1.736)是与未接受肾脏替代疗法的患者潜在不当处方风险增加相关的唯一独立因素。
    结论:我们的研究表明,在两个研究组中约有三分之一的患者中,潜在的不适当处方是一种相对常见的现象。处方药的数量是与两组潜在不适当处方风险增加相关的主要因素。
    BACKGROUND: This study aimed to compare the prevalence of potentially inappropriately prescribed drugs in hemodialysis patients and patients with chronic kidney disease who did not require renal replacement therapy, as well as to identify risk factors associated with potentially inappropriate prescribing.
    METHODS: The study was designed as a cross-sectional study conducted at the Department of Nephrology, Clinical Center in Nis, Serbia. The patients were divided into two groups: (1) patients on hemodialysis treatment and (2) patients with various degrees of chronic kidney disease without renal replacement therapy. The presence or absence of potentially inappropriate prescribing was determined using the 2015 AGS Beers criteria.
    RESULTS: The study included a total of 218 patients aged 65 years and over. The number of patients with potentially inappropriate prescribed drugs did not differ significantly (chi-square = 0.000, p = 1.000) between patients on hemodialysis (27 of 83, i.e., 32.5%) and patients with various degrees of chronic kidney disease without renal replacement therapy (44 of 135, i.e., 32.6%). Factors associated with potentially inappropriate prescribing in hemodialysis patients were the number of drugs (hazard ratio [HR] = 1.919, 95% confidence interval [CI]: 1.325-2.780) and number of comorbidities (HR = 1.743, 95% CI: 1.109-2.740). The number of drugs (HR = 1.438, 95% CI: 1.191-1.736) was the only independent factor associated with increased risk of potentially inappropriate prescribing in patients without renal replacement therapy.
    CONCLUSIONS: Our study showed that potentially inappropriate prescribing is a relatively frequent phenomenon present in about a third of patients in both study groups. The number of prescribed drugs was the main factor associated with the increased risk of potentially inappropriate prescribing in both groups.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:潜在不适当的处方(PIP)通常与不良健康结果的高风险相关。因此,在老年人中识别PIP很重要。然而,没有明确的优先策略来选择需要处方审查的患者.
    目的:本研究的目的是评估老年人高危(ISAR)评分与PIP数量之间的关联。
    方法:进行为期12个月的回顾性医院研究。PIPs,包括潜在的不适当药物(PIMs)和潜在的处方遗漏(PPOs),使用STOPP/START工具检测到。进行多元线性回归以确定与PIP数量相关的因素。灵敏度,特异性,尤登指数,并计算ROC曲线以确定ISAR评分的预测能力。
    结果:本研究包括266条记录。分析导致检测到420个PIM和210个PPO,患病率分别为80.1%和54.9%,分别。多元线性回归显示ISAR评分(p=0.041),药物数量(p<0.001)是PIP的决定因素。药物的数量仍然是PIM数量的唯一决定因素(p<0.001),而生活在疗养院是PPO数量的唯一决定因素(p=0.036)。
    结论:研究表明,ISAR评分和用药数量与PIP数量独立相关。考虑使用ISAR评分和药物的数量可能是有用的策略,可以优先考虑应使用明确标准评估处方适当性的患者。
    BACKGROUND: Potentially inappropriate prescribing (PIP) is usually associated with a higher risk of adverse health outcomes. It is therefore important to identify PIP in older adults. However, there are no clear prioritisation strategies to select patients requiring prescription reviews.
    OBJECTIVE: The aim of this study was to assess the association between the identification of seniors at risk (ISAR) score and the number of PIPs.
    METHODS: A 12-month retrospective hospital-based study was conducted. PIPs, including potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs), were detected using the STOPP/START tool. Multivariate linear regressions were conducted to identify factors associated with the number of PIPs. Sensitivity, specificity, Youden index, and ROC curve were calculated to determine the predictive power of ISAR score.
    RESULTS: This study included 266 records. The analysis led to the detection of 420 PIMs and 210 PPOs, with a prevalence of 80.1% and 54.9%, respectively. Multivariate linear regression revealed that the ISAR score (p = 0.041), and the number of medications (p < 0.001) were determinants of PIP. The number of medications remained the sole determinant of the number of PIMs (p < 0.001), while living in a nursing home was the only determinant of the number of PPOs (p = 0.036).
    CONCLUSIONS: The study showed that the ISAR score and the number of medications were independently associated with the number of PIPs. Considering the use of the ISAR score and the number of medications may be useful strategies to prioritise patients for whom prescribing appropriateness should be assessed using explicit criteria.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:几十年来,美国的药物利用率逐年增加。随着老年人服用更多的药物,他们暴露于药物-药物或药物-疾病相互作用的风险较高。美国老年医学会在2019年更新了他们在老年人中使用潜在不适当药物(PIM)的啤酒标准。这项研究的目的是评估2019Beers标准中包含的药物利用率。
    方法:使用2020日历年的MedicareD部分提供者利用率和支付数据公共使用文件进行了分析。2019年啤酒标准中确定的药物被应用于分析。评估了两类药物:(1)“避免”和(2)“谨慎使用”。
    结果:2020年,向65岁及以上的Medicare患者分发了5600万张处方,建议毫无例外地避免使用(占所有处方的4.7%),总计9.57亿美元的药物费用。此类中使用最多的药物类别是苯二氮卓类药物(25,949,994处方),“Z药”(6,204,909处方),长效磺脲类药物(5,306,577处方),第一代抗组胺药(5,049,289处方),和三环抗抑郁药(4,190,062处方)。此外,向65岁及65岁以上的Medicare受益人分发了1.35亿张处方,其中Beers标准指出要谨慎使用(占所有处方的11.3%)超过28.5亿美元的药物费用。这一类最常用的药物是利尿剂(74,599,126处方),选择性5-羟色胺再摄取抑制剂(30,033,121处方),5-羟色胺和去甲肾上腺素再摄取抑制剂(11,858,968处方),曲马多(11,450,878处方),和米氮平(5,737,304处方)。
    结论:即使存在AGS啤酒在老年人中使用PIM标准及其持续更新的版本,分配给MedicareD部分的药物中有16%可能不合适。需要未来的研究来评估这是否导致使用这些PIM的老年人的预后恶化。
    BACKGROUND: Medication utilization has been increasing in the U.S. year-over-year for several decades. As older adults take more medications, there is a higher risk of them being exposed to drug-drug or drug-disease interactions. The American Geriatrics Society in 2019 updated their Beers Criteria for Potentially Inappropriate Medication (PIM) Use in Older Adults. The objective of this study was to assess the prevalence of utilization of medications included in the 2019 Beers Criteria.
    METHODS: An analysis was conducted using the Medicare Part D Provider Utilization and Payment Data Public Use File for calendar-year 2020. Medications identified in the 2019 Beers Criteria were applied to the analysis. Two categories of medications were assessed: (1) \"Avoid\" and (2) \"Use With Caution.\"
    RESULTS: In 2020, 56 million prescriptions were dispensed to Medicare patients 65 years and older that are recommended to be avoided without exception (4.7% of all prescriptions) totaling $957 million in medication costs. The most utilized medication classes in this category were benzodiazepines (25,949,994 prescriptions), \"Z-drugs\" (6,204,909 prescriptions), long-acting sulfonylureas (5,306,577 prescriptions), 1st-generation antihistamines (5,049,289 prescriptions), and tricyclic antidepressants (4,190,062 prescriptions). Additionally, 135 million prescriptions were dispensed to Medicare beneficiaries 65 years and older for medications which the Beers Criteria states to use caution (11.3% of all prescriptions) exceeding $2.85 billion in medication costs. The most utilized medications for this category were diuretics (74,599,126 prescriptions), selective serotonin reuptake inhibitors (30,033,121 prescriptions), serotonin and norepinephrine reuptake inhibitors (11,858,968 prescriptions), tramadol (11,450,878 prescriptions), and mirtazapine (5,737,304 prescriptions).
    CONCLUSIONS: Even with the existence of the AGS Beers Criteria for PIM Use in Older Adults and its continued updated versions, 16% of medications dispensed to Medicare Part D were potentially inappropriate. Future studies are needed to assess if this has led to worsened outcomes among older adults who utilized these PIM.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:由于各种原因,可能不适当的处方在患有多种疾病的老年人中很常见,从同时应用多个单疾病临床指南到分散治疗。全球范围内已经实施了药物审查等干预措施,以减少老年人的不适当处方。然而,在新加坡公立医院的门诊诊所中,此类干预措施的可实施性不足。因此,Pro-M研究旨在评估在新加坡老年医学门诊实施医师-药剂师协同护理干预的可行性,以促进为老年人提供适当的处方.
    方法:这是一个单臂,非随机可行性研究使用的前后评估设计。本研究包括两部分:(1)干预实施阶段(6个月)和(2)评估阶段(3个月)。符合条件的患者将通过便利抽样从新加坡两家公立医院的老年医学门诊诊所招募。Pro-M干预的主要组成部分是:(1)药剂师促进的药物审查,对任何药物问题的反馈和对医生的潜在建议,(2)医生向其他相关处方者传达变更。评估阶段将涉及调查和访谈参与实施干预措施的医生和药剂师。将采用混合方法进行数据收集和分析。将使用Proctor的实施结果对定量和定性结果进行三角测量和报告:适当性,穿透力,可接受性,保真度,可行性,和可持续性。将在研究的同时进行基本成本分析。
    结论:这是一项第2阶段研究,旨在测试在干预措施的第1阶段开发过程中实施与利益相关者共同创建的干预措施的可行性,以优化对患有多种疾病的老年人的处方。该实施将使用Proctor的实施结果进行评估,以提供对该过程的见解以及在门诊诊所常规实践中对患有多发病率的老年人实施药物审查的可行性。从这项研究中收集的数据将为后续的扩大研究提供信息。
    背景:ClinicalTrials.gov标识符:NCT05756478。2023年3月6日注册。
    BACKGROUND: Potentially inappropriate prescribing is common among older adults with multimorbidity due to various reasons, from concurrent application of multiple single-disease clinical guidelines to fragmentation of care. Interventions such as medication review have been implemented worldwide to reduce inappropriate prescribing for older adults. However, the implementability of such interventions are underexplored in the outpatient clinics in Singapore\'s public hospitals. Hence, the Pro-M study aims to assess the feasibility of implementing a physician-pharmacist collaborative care intervention in geriatric medicine outpatient clinics to facilitate appropriate prescribing for older adults in Singapore.
    METHODS: This is a single-arm, non-randomised feasibility study using a pre-post evaluation design. This study consists of two parts: (1) implementation phase of the intervention (6 months) and an (2) evaluation phase (3 months). Eligible patients will be recruited from geriatric medicine outpatient clinics at two public hospitals in Singapore through convenience sampling. The main components of the Pro-M intervention are: (1) pharmacist-facilitated medication reviews with feedback on any medication issues and potential recommendations to physicians, and (2) physicians communicating changes to other relevant prescribers. The evaluation phase will involve surveying and interviewing physicians and pharmacists involved in the implementation of the intervention. A mixed-method approach will be employed for data collection and analysis. The quantitative and qualitative findings will be triangulated and reported using Proctor\'s implementation outcomes: appropriateness, penetration, acceptability, fidelity, feasibility, and sustainability. A basic cost analysis will be conducted alongside the study.
    CONCLUSIONS: This is a phase 2 study to test the feasibility of implementing an intervention that was co-created with stakeholders during phase 1 development of an intervention to optimise prescribing for older adults with multimorbidity. The implementation will be assessed using Proctor\'s implementation outcomes to provide insights on the process and the feasibility of implementing medication reviews for older adults with multimorbidity as a routine practice in outpatient clinics. Data collected from this study will inform a subsequent scale-up study.
    BACKGROUND: ClinicalTrials.gov Identifier: NCT05756478. Registered on 06 March 2023.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:本研究旨在确定65岁以上急性入院患者中潜在不适当处方(PIP)和潜在处方遗漏(PPOs)的患病率及其与ADR相关入院的关系。
    方法:从老龄化人群的药物不良反应(ADAPT)队列中提取有关药物和发病率的信息(N=798:N=361例ADR相关入院;437例非ADR相关入院)。PIP和PPO使用Beers标准2019和STOPP/START版本2进行评估。多变量逻辑回归(调整后的比值比(AOR),95CI)用于检查PIP,PPO和ADR相关的招生,调整协变量(年龄,性别,合并症,多药房)。
    结果:总计,715名(90%;95%CI87-92%)患者的啤酒标准≥1,555例(70%;95%CI66-73%)的STOPP标准≥1,666例(83%;95%CI81-86%)的START标准≥1。至少开了一杯啤酒(aOR=1.66,95%CI=1.00-2.77),或符合STOPP(aOR=1.07,95%CI=0.79-1.45)或START(aOR=0.72;95CI=0.50-1.06)标准或符合PIP/PPO标准的数量与ADR相关入院无显著相关性.患者开了某些药物类别(例如,抗血小板药,利尿剂)根据个人PIP标准更有可能发生ADR相关入院。
    结论:该队列中PIP和PPO的患病率很高,但与ADR相关的入院无关。
    BACKGROUND: This study aimed to determine the prevalence of potentially inappropriate prescribing (PIP) and potential prescribing omissions (PPOs) and their association with ADR-related hospital admissions in patients aged ≥ 65 years admitted acutely to the hospital.
    METHODS: Information on medications and morbidities was extracted from the Adverse Drug Reactions in an Ageing Population (ADAPT) cohort (N = 798: N = 361 ADR-related admissions; 437 non-ADR-related admissions). PIP and PPOs were assessed using Beers Criteria 2019 and STOPP/START version 2. Multivariable logistic regression (adjusted odds ratios (aOR), 95%CI) was used to examine the association between PIP, PPOs and ADR-related admissions, adjusting for covariates (age, gender, comorbidity, polypharmacy).
    RESULTS: In total, 715 (90%; 95% CI 87-92%) patients had ≥1 Beers Criteria, 555 (70%; 95% CI 66-73%) had ≥ 1 STOPP criteria and 666 patients (83%; 95% CI 81-86%) had ≥ 1 START criteria. Being prescribed at least one Beers (aOR = 1.66, 95% CI = 1.00-2.77), or meeting STOPP (aOR = 1.07, 95% CI = 0.79-1.45) or START (aOR = 0.72; 95%CI = 0.50-1.06) criteria or the number of PIP/PPO criteria met was not significantly associated with ADR-related admissions. Patients prescribed certain drug classes (e.g., antiplatelet agents, diuretics) per individual PIP criteria were more likely to have an ADR-related admission.
    CONCLUSIONS: There was a high prevalence of PIP and PPOs in this cohort but no association with ADR-related admissions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:多重用药和潜在的不适当处方(PIP)在人口老龄化中日益受到关注。它们有增加不良反应的风险,医学互动,和管理药物的困难。葡萄牙很少有研究评估初级保健中多重用药和PIP的患病率。以前在葡萄牙的初级保健环境中没有使用欧盟(EU)(7)-PIM(潜在不适当的药物)列表工具进行过研究。在这项研究中,我们旨在评估葡萄牙两个家庭保健单位中多重用药和PIP的患病率.方法:回答这个问题,在一项描述性观察性横向研究中,我们纳入了来自两个家庭健康单位的361名老年患者的样本.我们随机选择患者,查阅了他们在过去12个月的处方记录,并应用了EU(7)-PIM列表工具,验证葡萄牙人口。然后使用描述性和推断性统计数据以及社会科学统计软件包(IBMSPSSStatisticsforWindows,IBM公司,版本24.0,阿蒙克,NY).
    结果:我们的结果显示,老年人群中多重用药的患病率为79.8%,PIP的患病率为73.4%。这些值高于文献中的预测值,但是论文中使用了不同的筛选工具。每位患者的平均处方药数量是一个单位中的9个,另一个单位中的7个,模式为每位患者11位。最确定的PIP相关药物是质子泵抑制剂,其中一个单位中有46.4%的患者,另一个单位中有43.7%的患者。我们还发现,在75岁以上的女性和患者中,PIP和多重用药的患病率具有统计学意义。
    结论:从患病率的角度来看,我们发现我们人群中PIP和多重用药的患病率高于预期.促成因素可能是葡萄牙人口老龄化指数较高,使用联合疗法的现代实践,以及使用不考虑患者个人临床病史的筛查工具。进一步的限制涉及仅包括在研究单位中随访的患者。即便如此,它建议同时解决PIP和多重药房问题,我们将努力对两个卫生团队进行PIP教育,多药,和开药。我们还强调需要将研究范围扩大到其他家庭保健单位。
    OBJECTIVE: Polypharmacy and potentially inappropriate prescribing (PIP) are growing concerns in the ageing population. They carry the risk of increasing adverse effects, medical interactions, and difficulties managing the medication. Few studies in Portugal evaluate the prevalence of polypharmacy and PIP in primary care. No previous studies in the primary care setting in Portugal have been conducted using the European Union (EU)(7)-PIM (potentially inappropriate medication) list tool. In this study, we aimed to estimate the prevalence of polypharmacy and PIP in two family health units in Portugal.  Methods: To answer this question, we enrolled a sample of 361 elderly patients from two family health units in a descriptive observational transversal study. We randomly selected patients, consulted their prescription records in the previous 12 months, and applied the EU(7)-PIM list tool, validated for the Portuguese population. The data was then analyzed using descriptive and inferential statistics and the Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, IBM Corp., Version 24.0, Armonk, NY).
    RESULTS: Our results showed a prevalence of 79.8% of polypharmacy in the elderly population and 73.4% of PIP. These values are higher than predicted in the literature, but different screening tools have been used among papers. The mean number of prescribed drugs per patient was nine in one unit and seven in the other, and the mode was eleven per patient. The most identified PIP-associated drugs were proton pump inhibitors in 46.4% of the patients in one unit and 43.7% in the other. We also found a statistically significant higher prevalence of PIP and polypharmacy in females and patients over 75 years.
    CONCLUSIONS: From a prevalence perspective, we found higher-than-expected prevalences of PIP and polypharmacy in our population. Contributing factors might be a higher ageing index in the Portuguese population, modern practices using combination therapy, and the use of a screening tool that does not take into account the personal clinical history of patients. Further limitations involve only including patients with follow-up in the units studied. Even so, it suggests both PIP and polypharmacy as concerns to address, and we will strive to educate both health teams on PIP, polypharmacy, and deprescribing. We also emphasize the need to widen the study to other family health units.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号